
TTRX Stock Forecast & Price Target
TTRX Analyst Ratings
Bulls say
Turn Therapeutics is attractive because its PermaFusion® platform addresses a core topical-drug limitation by delivering liquid APIs as stable nanodroplets with deep penetration, preserved potency, and reduced side effects, while remaining API-agnostic across dermatology, infectious disease, and vaccines. GX-03 adds conviction: it has been validated across three FDA-cleared medical devices, supported by over 200,000 human uses with no reported adverse events, and is now in a 120-135 patient Phase 2 eczema trial that began in July 2025 with no safety or tolerability concerns reported to date. The company also has meaningful non-dilutive upside from partnerships, including up to $69.55 million in milestones plus mid-single digit royalties from Mimedx and a 2025 Medline agreement, which together help fund development while preserving capital efficiency.
Bears say
Turn Therapeutics is a clinical-stage biotech with promising GX-03 data, but the investment case is weakened by the long, expensive road from Phase 2 to Phase 3 and the likelihood that near-term upside is already reflected in the current share price. The company faces meaningful financing risk, including a GEM facility for up to $85.0 million at 90% of the average closing price over 15 trading days, which signals potential dilution and may still fall short of future capital needs. In addition, fewer than 100,000 shares have traded on most days, Bradley Burnam controlled about 52% of voting power as of June 30, 2025, and unresolved legal, supply-chain, and contractor dependencies add execution risk.
This aggregate rating is based on analysts' research of Turn Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Turn Therapeutics Inc (TTRX) Forecast
TTRX Analyst Forecast & Price Prediction
Start investing in TTRX
Order type
Buy in
Order amount
Est. shares
0 shares